AP494A - Androstenone derivative. - Google Patents

Androstenone derivative. Download PDF

Info

Publication number: AP494A
Authority: AP; ARIPO
Prior art keywords: compound; formula; testosterone; mediated disease; pharmaceutically acceptable
Prior art date: 1993-09-17

Application number

APAP/P/1994/000669A

Other languages

English (en)

Other versions

AP9400669A0 (en

Inventor

Kenneth William Batchelor

Stephen Vernon Fyre

Original Assignee

Glaxo Wellcome Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-09-17

Filing date

1994-09-15

Publication date

1996-05-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22407744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP494(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-09-15 Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc

1994-10-31 Publication of AP9400669A0 publication Critical patent/AP9400669A0/xx

1996-05-15 Application granted granted Critical

1996-05-15 Publication of AP494A publication Critical patent/AP494A/en

Links

HFVMLYAGWXSTQI-QYXZOKGRSA-N 5alpha-androst-16-en-3-one Chemical class C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CC[C@H]21 HFVMLYAGWXSTQI-QYXZOKGRSA-N 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 74
238000000034 method Methods 0.000 claims description 19
238000006243 chemical reaction Methods 0.000 claims description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
229960003604 testosterone Drugs 0.000 claims description 15
239000003098 androgen Substances 0.000 claims description 14
201000010099 disease Diseases 0.000 claims description 14
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 14
239000012453 solvate Substances 0.000 claims description 12
206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 8
208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 8
230000001404 mediated effect Effects 0.000 claims description 8
125000006239 protecting group Chemical group 0.000 claims description 7
208000002874 Acne Vulgaris Diseases 0.000 claims description 5
241000124008 Mammalia Species 0.000 claims description 5
206010000496 acne Diseases 0.000 claims description 5
230000002401 inhibitory effect Effects 0.000 claims description 5
201000004384 Alopecia Diseases 0.000 claims description 4
206010068168 androgenetic alopecia Diseases 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
230000008569 process Effects 0.000 claims description 4
108090000790 Enzymes Proteins 0.000 claims description 3
102000004190 Enzymes Human genes 0.000 claims description 3
206010020112 Hirsutism Diseases 0.000 claims description 3
206010060862 Prostate cancer Diseases 0.000 claims description 3
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
102000004316 Oxidoreductases Human genes 0.000 claims description 2
108090000854 Oxidoreductases Proteins 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
230000002140 halogenating effect Effects 0.000 claims description 2
230000002265 prevention Effects 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 2
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 26
239000000203 mixture Substances 0.000 description 23
150000003431 steroids Chemical class 0.000 description 16
239000000243 solution Substances 0.000 description 15
238000009472 formulation Methods 0.000 description 14
239000003112 inhibitor Substances 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
239000004615 ingredient Substances 0.000 description 12
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
210000002307 prostate Anatomy 0.000 description 9
239000007787 solid Substances 0.000 description 9
238000012360 testing method Methods 0.000 description 9
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
239000002253 acid Substances 0.000 description 7
238000003556 assay Methods 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
239000000725 suspension Substances 0.000 description 7
HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 6
-1 4-MA (McConnell Chemical class 0.000 description 6
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
239000000543 intermediate Substances 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
210000001589 microsome Anatomy 0.000 description 6
239000003921 oil Substances 0.000 description 6
239000011541 reaction mixture Substances 0.000 description 6
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
108010044467 Isoenzymes Proteins 0.000 description 5
230000001919 adrenal effect Effects 0.000 description 5
239000012267 brine Substances 0.000 description 5
230000000694 effects Effects 0.000 description 5
239000000706 filtrate Substances 0.000 description 5
229960004039 finasteride Drugs 0.000 description 5
238000010992 reflux Methods 0.000 description 5
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
239000000126 substance Substances 0.000 description 5
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
239000006260 foam Substances 0.000 description 4
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
229910052938 sodium sulfate Inorganic materials 0.000 description 4
235000011152 sodium sulphate Nutrition 0.000 description 4
108010085346 steroid delta-isomerase Proteins 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000003826 tablet Substances 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 3
101710088194 Dehydrogenase Proteins 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
108090000769 Isomerases Proteins 0.000 description 3
102000004195 Isomerases Human genes 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
230000002950 deficient Effects 0.000 description 3
239000008187 granular material Substances 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
239000001257 hydrogen Substances 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
239000000463 material Substances 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000000741 silica gel Substances 0.000 description 3
229910002027 silica gel Inorganic materials 0.000 description 3
239000002002 slurry Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000000829 suppository Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
RZYHXKLKJRGJGP-UHFFFAOYSA-N 2,2,2-trifluoro-n,n-bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)N([Si](C)(C)C)C(=O)C(F)(F)F RZYHXKLKJRGJGP-UHFFFAOYSA-N 0.000 description 2
150000000520 4-azasteroids Chemical class 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
102000009151 Luteinizing Hormone Human genes 0.000 description 2
108010073521 Luteinizing Hormone Proteins 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
230000009471 action Effects 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
229910021529 ammonia Inorganic materials 0.000 description 2
239000003708 ampul Substances 0.000 description 2
230000003466 anti-cipated effect Effects 0.000 description 2
239000000010 aprotic solvent Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000006172 buffering agent Substances 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
229940125810 compound 20 Drugs 0.000 description 2
239000006071 cream Substances 0.000 description 2
239000012043 crude product Substances 0.000 description 2
FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000001085 differential centrifugation Methods 0.000 description 2
238000004821 distillation Methods 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 2
239000000284 extract Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
230000008570 general process Effects 0.000 description 2
150000004820 halides Chemical class 0.000 description 2
238000000265 homogenisation Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000006210 lotion Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
229940040129 luteinizing hormone Drugs 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
238000000465 moulding Methods 0.000 description 2
239000002674 ointment Substances 0.000 description 2
150000002894 organic compounds Chemical class 0.000 description 2
MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
229910003446 platinum oxide Inorganic materials 0.000 description 2
229920000728 polyester Polymers 0.000 description 2
229920001296 polysiloxane Polymers 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
239000012049 topical pharmaceutical composition Substances 0.000 description 2
241000701447 unidentified baculovirus Species 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
LTCAWJFJFVGUNT-TZUPDSNESA-N (3as,3bs,9ar,9bs,11as)-9a,11a-dimethyl-1,2,3,3a,3b,4,6,8,9,9b,10,11-dodecahydroindeno[5,4-f]quinolin-7-one Chemical compound C1C=C2NC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 LTCAWJFJFVGUNT-TZUPDSNESA-N 0.000 description 1
HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
MUMGGOZAMZWBJJ-JQSYSRDDSA-N (8r,9s,10r,13s,14s,17s)-17-hydroxy-10,13-dimethyl-1,2,6,7-tetratritio-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2C([3H])C([3H])C3=CC(=O)C([3H])C([3H])[C@]3(C)[C@H]21 MUMGGOZAMZWBJJ-JQSYSRDDSA-N 0.000 description 1
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
XWMVIJUAZAEWIE-UHFFFAOYSA-N 2,5-bis(trifluoromethyl)aniline Chemical compound NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F XWMVIJUAZAEWIE-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
JYLNVJYYQQXNEK-UHFFFAOYSA-N 3-amino-2-(4-chlorophenyl)-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(CN)C1=CC=C(Cl)C=C1 JYLNVJYYQQXNEK-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
239000004821 Contact adhesive Substances 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
VAPSMQAHNAZRKC-PQWRYPMOSA-N Epristeride Chemical compound C1C=C2C=C(C(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC2 VAPSMQAHNAZRKC-PQWRYPMOSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010019851 Hepatotoxicity Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
206010036049 Polycystic ovaries Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229940123934 Reductase inhibitor Drugs 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000000951 adrenergic alpha-1 receptor antagonist Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
229960003473 androstanolone Drugs 0.000 description 1
229960005471 androstenedione Drugs 0.000 description 1
AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
150000001448 anilines Chemical class 0.000 description 1
230000002280 anti-androgenic effect Effects 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
239000000051 antiandrogen Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
WGXZDYPGLJYBJW-UHFFFAOYSA-N chloroform;propan-2-ol Chemical compound CC(C)O.ClC(Cl)Cl WGXZDYPGLJYBJW-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
229940125846 compound 25 Drugs 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
229940125436 dual inhibitor Drugs 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229960002074 flutamide Drugs 0.000 description 1
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
238000007429 general method Methods 0.000 description 1
210000002503 granulosa cell Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000007686 hepatotoxicity Effects 0.000 description 1
231100000304 hepatotoxicity Toxicity 0.000 description 1
239000008241 heterogeneous mixture Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
108091008039 hormone receptors Proteins 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
238000007327 hydrogenolysis reaction Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
239000005414 inactive ingredient Substances 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
210000002332 leydig cell Anatomy 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
GSYSFVSGPABNNL-UHFFFAOYSA-N methyl 2-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)acetate Chemical group COC(=O)C(P(=O)(OC)OC)NC(=O)OCC1=CC=CC=C1 GSYSFVSGPABNNL-UHFFFAOYSA-N 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
JBGNFLUETJDDBA-UHFFFAOYSA-N n,n-bis(trifluoromethyl)aniline Chemical compound FC(F)(F)N(C(F)(F)F)C1=CC=CC=C1 JBGNFLUETJDDBA-UHFFFAOYSA-N 0.000 description 1
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
229940096978 oral tablet Drugs 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000002304 perfume Substances 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
201000010065 polycystic ovary syndrome Diseases 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000098 polyolefin Polymers 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
239000012286 potassium permanganate Substances 0.000 description 1
229960002847 prasterone Drugs 0.000 description 1
229940072254 proscar Drugs 0.000 description 1
201000007094 prostatitis Diseases 0.000 description 1
238000011552 rat model Methods 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
239000011369 resultant mixture Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
229920005573 silicon-containing polymer Polymers 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
WSRBRQQGWDWSON-UHFFFAOYSA-M sodium;3,7-dimethylpurine-2,6-dione;2-hydroxybenzoate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O.CN1C(=O)NC(=O)C2=C1N=CN2C WSRBRQQGWDWSON-UHFFFAOYSA-M 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
229960001693 terazosin Drugs 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
229940100640 transdermal system Drugs 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
- C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/82—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
- C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
- C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/14—Benz[f]indenes; Hydrogenated benz[f]indenes

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

APAP/P/1994/000669A 1993-09-17 1994-09-15 Androstenone derivative. AP494A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US12328093A	1993-09-17	1993-09-17

Publications (2)

Publication Number	Publication Date
AP9400669A0 AP9400669A0 (en)	1994-10-31
AP494A true AP494A (en)	1996-05-15

Family

ID=22407744

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1994/000669A AP494A (en)	1993-09-17	1994-09-15	Androstenone derivative.

Country Status (40)

Country	Link
US (2)	US5565467A (fr)
EP (1)	EP0719278B1 (fr)
JP (1)	JP2904310B2 (fr)
KR (1)	KR100364953B1 (fr)
CN (1)	CN1057771C (fr)
AP (1)	AP494A (fr)
AT (1)	ATE162199T1 (fr)
AU (1)	AU690925B2 (fr)
BG (1)	BG62363B1 (fr)
BR (1)	BR1100329A (fr)
CA (2)	CA2170047C (fr)
CY (2)	CY2219B1 (fr)
CZ (1)	CZ286069B6 (fr)
DE (2)	DE10399022I2 (fr)
DK (1)	DK0719278T3 (fr)
EE (1)	EE03241B1 (fr)
ES (1)	ES2113127T3 (fr)
FI (1)	FI115216B (fr)
GR (1)	GR3026144T3 (fr)
HR (1)	HRP940563B1 (fr)
HU (1)	HU220060B (fr)
IL (1)	IL110978A (fr)
IS (1)	IS1713B (fr)
LU (1)	LU91027I2 (fr)
MY (1)	MY119778A (fr)
NL (1)	NL300122I2 (fr)
NO (2)	NO306117B1 (fr)
NZ (1)	NZ274642A (fr)
OA (1)	OA10575A (fr)
PE (1)	PE15095A1 (fr)
PL (1)	PL180002B1 (fr)
RO (1)	RO117455B1 (fr)
RU (1)	RU2140926C1 (fr)
SA (1)	SA94150231B1 (fr)
SG (1)	SG52650A1 (fr)
SI (1)	SI0719278T1 (fr)
SK (1)	SK281869B6 (fr)
TW (1)	TW369521B (fr)
WO (1)	WO1995007927A1 (fr)
ZA (2)	ZA947119B (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0641209A4 (fr) *	1992-05-20	1995-08-23	Merck & Co Inc	NOUVEAUX DERIVES 17-ESTER, AMIDE ET CETONE DE 3-OXO-4-AZASTEROIDES UTILISES COMME INHIBITEURS DE 5a-REDUCTASE.
AU5323694A (en) *	1992-10-06	1994-04-26	Merck & Co., Inc.	17beta -carboxanilides of 4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors
TW408127B (en) *	1993-09-17	2000-10-11	Glaxo Inc	Androstenones
US5547957A (en)	1993-10-15	1996-08-20	Merck & Co., Inc.	Method of treating androgenic alopecia with 5-α reductase inhibitors
TW382595B (en) *	1993-10-15	2000-02-21	Merck & Co Inc	Pharmaceutical composition for use in arresting and reversing androgenic alopecia
ES2125495T3 (es) *	1993-10-21	1999-03-01	Merck & Co Inc	4-aza-androstano 16 sustituidos inhibidores de la isoenzima 5-alfa-reductasa 1.
US5817818A (en) *	1994-09-16	1998-10-06	Glaxo Wellcome Inc.	Androstenones
US6001844A (en) *	1995-09-15	1999-12-14	Merck & Co., Inc.	4-Azasteroids for treatment of hyperandrogenic conditions
US5872126A (en) *	1996-09-06	1999-02-16	Merck & Co., Inc.	Methods and compositions for treating preterm labor
US5935968A (en) *	1997-03-17	1999-08-10	Merck & Co., Inc.	Methods for treating polycystic ovary syndrome
GB9717428D0 (en) *	1997-08-19	1997-10-22	Glaxo Group Ltd	Pharmaceutical composition
AU731576B2 (en) *	1997-10-28	2001-04-05	Merck & Co., Inc.	Prevention of precipitated acute urinary retention
TR200002784T2 (tr) *	1998-03-11	2000-12-21	Endorecherche, Inc	Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar
EP1321146A3 (fr) *	1998-03-11	2004-06-02	Endorecherche Inc.	Inhibiteurs de la 17beta-hydroxysteroide deshydrogénase du type 5 et du type 3 ainsi que leurs méthodes d'utilisation
US5998427A (en) *	1998-05-14	1999-12-07	Glaxo Wellcome Inc.	Androstenones
AU4701299A (en) *	1998-06-23	2000-01-10	Stuart R. Adler	Therapeutic applications of estrogenic carboxylic acids
AU2512800A (en) *	1999-02-03	2000-08-25	Eli Lilly And Company	Alpha1-adrenergic receptor antagonists
IL146284A0 (en)	1999-05-04	2002-07-25	Strakan Ltd	Androgen glycosides and pharmaceutical compositions containing the same
US6645974B2 (en)	2001-07-31	2003-11-11	Merck & Co., Inc.	Androgen receptor modulators and methods for use thereof
EP1434786A4 (fr) *	2001-10-03	2009-03-25	Merck & Co Inc	Androstane 17-beta-carboxamides en tant que modulateurs de recepteurs d'androgenes
DK1468983T3 (da) *	2002-01-25	2008-01-07	Asahi Glass Co Ltd	Fremgangsmåde til fremstilling af 2,5-bis(trifluormethyl)nitrobenzen
EP1743656A3 (fr)	2002-04-24	2007-03-07	Boehringer Ingelheim Pharma GmbH & Co. KG	Combinaison pharmaceutique pour le traitement de l'hyperplasie prostatique benigne ou pour la prévention à long terme de la rétention urinaire aigue
JP4516839B2 (ja) *	2002-04-30	2010-08-04	メルク・シャープ・エンド・ドーム・コーポレイション	アンドロゲン受容体修飾因子としての４−アザステロイド誘導体
US7326717B2 (en) *	2003-05-06	2008-02-05	L'oreal	Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof
US7022854B2 (en) *	2003-07-17	2006-04-04	Dr. Reddy's Laboratories, Limited	Forms of dutasteride and methods for preparation thereof
US20050059692A1 (en) *	2003-09-09	2005-03-17	Dr. Reddy's Laboratories Limited	Process for the preparation of 17beta-N-[2,5-bis(trifluoromethyl)phenyl] carbamoyl-4-aza-5-alpha-androst-1-en-3-one
WO2005092341A1 (fr) *	2004-03-22	2005-10-06	Ranbaxy Laboratories Limited	Therapie combinee destinee a reduire les symptomes des voies urinaires
EP1734963A4 (fr) *	2004-04-02	2008-06-18	Merck & Co Inc	Methode destinee a traiter des hommes presentant des troubles metaboliques et anthropometriques
US7482359B2 (en) *	2004-08-25	2009-01-27	Merck & Co., Inc.	Androgen receptor modulators
US7998970B2 (en) *	2004-12-03	2011-08-16	Proteosys Ag	Use of finasteride, dutasteride and related compounds for the prevention or treatment of neurologically-associated disorders
US20060193804A1 (en) *	2005-02-24	2006-08-31	L'oreal	Haircare use of cyclic amine derivatives
AU2006229840B2 (en) *	2005-03-25	2010-12-23	Merck Sharp & Dohme Corp.	Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
EP1945615A2 (fr) *	2005-11-10	2008-07-23	Dr. Reddy's Laboratories Ltd.	Préparation de dutastéride
EP1897533A1 (fr) *	2006-09-08	2008-03-12	Revotar Biopharmaceuticals AG	Utilisation de 1,6-Bis[3-(3-carboxyméthylphényl)-4-(2-alpha-D-mannopyranosyl-oxy)-phényl]hexane pour la préparation des compositions cosmétiques.
EP1946756A1 (fr) *	2007-01-17	2008-07-23	Revotar Biopharmaceuticals AG	Utilisation d'entacapone dans les compositions cosmétiques, dermatologiques et pharmaceutiques
FR2920309B1 (fr)	2007-08-28	2010-05-28	Galderma Res & Dev	Utilisation de travoprost pour traiter la chute des cheveux
US20090076057A1 (en) *	2007-09-13	2009-03-19	Protia, Llc	Deuterium-enriched dutasteride
EP2050436A1 (fr)	2007-12-21	2009-04-22	Siegfried Generics International AG	Composition pharmaceutique qui comporte de la dutastéride
AR070313A1 (es) *	2008-01-03	2010-03-31	Gador Sa	Un procedimiento para preparar una forma solida y cristalina de dutasteride, una forma polimorfica del compuesto (forma iii) y una composicion farmaceutica que incluye dicha forma
FR2929117B1 (fr)	2008-03-28	2010-05-07	Oreal	Utilisation de l'association du 2,4-diaminopyrimidine 3-n-oxyde et du madecassosside et/ou du terminoloside pour induire et/ou stimuler la croissance de ces fibres keratiniques humaines et/ou freiner leur chute
FR2929118B1 (fr)	2008-03-28	2010-05-07	Oreal	Utilisation de l'association de madecassoside et/ou de terminoloside et d'une arginine pour induire et/ou stimuler la croissance de ces fibres keratiniques humaines et/ou freiner leur chute
CN102215845A (zh)	2008-04-03	2011-10-12	哈博生物科学公司	药学试剂的固体形式
US20100048598A1 (en) *	2008-08-21	2010-02-25	Sateesh Kandavilli	Topical compositions comprising 5-alpha reductase inhibitors
CN101759762B (zh) *	2008-11-06	2013-03-20	天津金耀集团有限公司	4ad在制备度他雄胺中的应用
US8563728B2 (en) *	2009-07-09	2013-10-22	Aurobindo Pharma Ltd.	Process for the preparation of Dutasteride
FR2949052B1 (fr)	2009-08-13	2015-03-27	Oreal	Procede de traitement cosmetique du cuir chevelu.
EP2468262A1 (fr)	2010-12-06	2012-06-27	Krka Tovarna Zdravil, D.D., Novo Mesto	Composition pharmaceutique contenant de la dutastéride
WO2012162776A1 (fr) *	2011-06-03	2012-12-06	Eurofarma Laboratórios S.A	Composition pharmaceutique pour le traitement de l'hyperplasie bénigne de la prostate
HU230730B1 (hu)	2011-06-30	2017-12-28	Richter Gedeon Nyrt	Eljárás (5alfa,17béta)-N-[2,5-bisz-(trifluormetil)-fenil]-3-oxo-4-aza-5-androszt-1-én-17-karbonsavamid előállítására
CN103059098B (zh) *	2011-10-24	2015-04-01	成都国为医药科技有限公司	一种度他雄胺的制备方法
US9622981B2 (en)	2011-11-17	2017-04-18	Mylan Inc.	Liquid-filled hard gel capsule pharmaceutical formulations
CN102382165B (zh) *	2011-12-02	2014-05-07	华润赛科药业有限责任公司	一种度他雄胺的制备方法
CN103554210A (zh) *	2012-01-05	2014-02-05	中国药科大学	甾体类5α-还原酶抑制剂、其制备方法及其医药用途
CN102532236B (zh) *	2012-01-05	2014-04-16	中国药科大学	甾体类5α-还原酶抑制剂、其制备方法及其医药用途
KR101976137B1 (ko)	2012-01-25	2019-05-09	한미약품 주식회사	두타스테라이드 함유 자가 유화 약물전달 시스템용 조성물 및 이의 제조 방법
WO2013158649A1 (fr)	2012-04-16	2013-10-24	Case Western Reserve University	Compositions et méthodes pour moduler l'activité 15-pgdh
WO2014002015A1 (fr)	2012-06-25	2014-01-03	Ranbaxy Laboratories Limited	Composition pharmaceutique comprenant du dutastéride
WO2014158875A1 (fr) *	2013-03-14	2014-10-02	Pellficure Pharmaceuticals Inc.	Nouvelle thérapie pour le carcinome de la prostate
CN103254268A (zh) *	2013-05-16	2013-08-21	寿光市富康化学工业有限公司	一种制备度他雄胺的工艺
BR102013020508B1 (pt)	2013-08-12	2021-01-12	Ems S/A.	Forma de dosagem que compreende um inibidor de esteroide 5-alfa-redutase e um bloqueador alfa, processo para a preparaçãode uma forma de dosagem e uso da forma de dosagem
US9789116B2 (en)	2013-10-15	2017-10-17	Case Western Reserve University	Compositions and methods of modulating short-chain dehydrogenase activity
ES2555485T1 (es)	2014-05-26	2016-01-04	Galenicum Health S.L.	Composiciones farmacéuticas que contienen un agente activo
CA3254372A1 (fr)	2014-12-05	2025-06-28	Case Western Reserve University	Compositions et procédés de modulation de la s-nitrosylation
KR101590072B1 (ko)	2014-12-23	2016-01-29	한미약품 주식회사	두타스테라이드를 포함하는 자가유화 약물전달 시스템용 조성물
BR112017019416B1 (pt) *	2015-03-13	2023-05-02	Dow Global Technologies Llc	Composição e processo para preparar uma composição
KR102503428B1 (ko)	2015-12-22	2023-02-24	한미약품 주식회사	두타스테라이드를 포함하는 경구용 연질 캡슐 제형용 포장재
BR112018068686A2 (pt)	2016-03-16	2019-01-15	Hanmi Pharm Ind Co Ltd	formulação de compósito de cápsula dura, formulação de compósito de dose fixa e método de preparação da formulação de compósito de cápsula dura
KR101716878B1 (ko)	2016-05-12	2017-03-15	주식회사 유유제약	글리세롤 지방산에스테르유도체 또는 프로필렌글리콜 지방산에스테르유도체를 함유한 두타스테리드와 타다라필의 복합 캡슐제제 조성물 및 이의 제조방법
WO2018102552A1 (fr)	2016-11-30	2018-06-07	Case Western Reserve University	Combinaisons d'inhibiteurs de 15-pgdh avec des corcostéroïdes et/ou des inhibiteurs du tnf et leurs utilisations
US11718589B2 (en)	2017-02-06	2023-08-08	Case Western Reserve University	Compositions and methods of modulating short-chain dehydrogenase
US11633409B2 (en)	2017-09-01	2023-04-25	Jw Pharmaceutical Corporation	Solid preparation comprising dutasteride and method for preparing same
KR101996597B1 (ko)	2017-10-13	2019-07-31	주식회사 유유제약	두타스테리드와 타다라필을 용해시킨 경구용 캡슐 제형의 복합제제
WO2019225924A1 (fr) *	2018-05-21	2019-11-28	(주)인벤티지랩	Microparticules comprenant du dutastéride et procédé de préparation associé
KR102281252B1 (ko)	2018-05-21	2021-07-23	(주)인벤티지랩	두타스테라이드를 포함하는 마이크로 입자 및 이의 제조 방법
KR102921276B1 (ko)	2018-11-21	2026-02-03	케이스 웨스턴 리저브 유니버시티	단쇄 데히드로게나아제 활성을 조절하는 조성물 및 방법
KR20200074759A (ko)	2018-12-17	2020-06-25	동국제약 주식회사	두타스테라이드를 함유하는 고형제제
MX2022014637A (es)	2020-05-20	2023-03-03	Rodeo Therapeutics Corp	Composiciones y metodos para modular la actividad de deshidrogenasas de cadena corta.
WO2024144084A1 (fr) *	2022-12-26	2024-07-04	주식회사 유영제약	Composition pharmaceutique de dutastéride à dose élevée sous forme de comprimé pour administration hebdomadaire et son procédé de préparation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0484094A2 (fr) *	1990-10-29	1992-05-06	Sankyo Company Limited	Azastéroides pour le traitement d'hypotrophie prostatique, leur préparation et usage

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4191759A (en) *	1978-04-13	1980-03-04	Merck & Co., Inc.	N-substituted-17β-carbamoylandrost-4-en-3-one 5α reductase inhibitors
AU527030B2 (en) *	1978-04-13	1983-02-10	Merck & Co., Inc.	4-aza-17-substituted-5a-androstan-3-ones
US4377584A (en) *	1978-04-13	1983-03-22	Merck & Co., Inc.	4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
US4220775A (en) *	1979-03-15	1980-09-02	Merck & Co., Inc.	Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors
US4317817A (en) *	1979-08-27	1982-03-02	Richardson-Merrell Inc.	Novel steroid 5α-reductase inhibitors
DK465481A (da) *	1980-11-21	1982-05-22	Hoffmann La Roche	Fremgangsmaade til fremstilling af d-homostemoider
US4760071A (en) *	1984-02-27	1988-07-26	Merck & Co., Inc.	17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
ATE67503T1 (de) *	1984-02-27	1991-10-15	Merck & Co Inc	17-beta-substituierte-4-aza-5-alpha-androstenon und ihre anwendung als 5-alpha-reduktaseinhibitoren.
US5049562A (en) *	1984-02-27	1991-09-17	Merck & Co., Inc.	17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α-reductase inhibitors
NZ211145A (en) *	1984-02-27	1988-10-28	Merck & Co Inc	4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
GB8505862D0 (en) *	1985-03-07	1985-04-11	Erba Farmitalia	Steroidic 5alpha-reductase inhibitors
DE3780778T2 (de) *	1986-11-20	1993-01-14	Merck & Co Inc	Topisches arzneimittel enthaltend 17-beta-methoxy-carbonyl-4-methyl-4-aza-5-alpha-androst-1-en-3-one.
US4845104A (en) *	1986-11-20	1989-07-04	Merck & Co., Inc.	Oxidized analogs of 17β-N-monosubstituted-carbamoyl-4-aza-5-α-androstan-3-ones
US5110939A (en) *	1987-01-28	1992-05-05	Smithkline Beecham Corporation	Intermediates in the preparation of steriod 5-alpha-reductase inhibitors
US4888336A (en) *	1987-01-28	1989-12-19	Smithkline Beckman Corporation	Steroid 5-alpha-reductase inhibitors
US4814324A (en) *	1987-03-06	1989-03-21	Merck & Co., Inc.	Sterol inhibitors of testosterone 5α-reductase
EP0285382B1 (fr) *	1987-04-03	1994-04-13	Merck & Co. Inc.	Traitement d'alopécia androgénique avec 17-bêta-n-monosubstitué-carbamoyl-4-aza-5-alpha-androst-1-en-3-ones
EP0285383B1 (fr) *	1987-04-03	1994-03-16	Merck & Co. Inc.	Traitement des carcinomes prostatiques avec des 17-bêta-n-monosubstitué-carbamoyl-4-aza-5-alpha-androst-1-en-ones
US5041433A (en) *	1987-04-29	1991-08-20	Smithkline Beecham Corporation	11-keto or hydroxy 3,5-diene steroids as inhibitors of steriod 5-α-reductase
US4910226A (en) *	1987-04-29	1990-03-20	Smithkline Beckman Corporation	Steroid 5-alpha-reductase inhibitors
ZA883034B (en) *	1987-04-29	1989-03-29	Smithkline Beckman Corp	Steroid 5-alpha-reductase inhibitors
NZ225100A (en) *	1987-06-29	1991-09-25	Merck & Co Inc	Reaction of steroids (including 4-azasteroids) with a silylating agent in the presence of a quinone to introduce a delta' double bond and silylated intermediates
WO1989011282A1 (fr) *	1988-05-25	1989-11-30	Smithkline Beckman Corporation	INHIBITEURS DE 5-alpha-REDUCTASE STEROIDE AROMATIQUE
US4954446A (en) *	1988-05-25	1990-09-04	Smithkline Beecham Corporation	Aromatic steroid 5-α-reductase inhibitors
US5237061A (en) *	1988-10-31	1993-08-17	Merck & Co., Inc.	Methods of synthesizing benign prostatic hypertropic agents and their intermediates
US4970205A (en) *	1988-12-23	1990-11-13	Smithkline Beecham Corporation	Sulfonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
US4946834A (en) *	1988-12-23	1990-08-07	Smithkline Beecham Corporation	Phosphonic acid substituted steroids as steroid 5α-reductase inhibitors
US4882319A (en) *	1988-12-23	1989-11-21	Smithkline Beckman Corporation	Phosphonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
US5026882A (en) *	1988-12-23	1991-06-25	Smithkline Beecham Corporation	Phosphinic acid substituted steroids as inhibitors of steroid 5α-reductase
US4937237A (en) *	1988-12-23	1990-06-26	Smithkline Beckman Corporation	Phosphinic acid substituted aromatic steroids as inhibitors of steroid 5-60 -reductase
US4966898A (en) *	1989-08-15	1990-10-30	Merrell Dow Pharmaceuticals Inc.	4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
US4966897A (en) *	1989-08-15	1990-10-30	Merrell Dow Pharmaceuticals Inc.	4-substituted 17β-(cyclopropyloxy)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
CA2023157A1 (fr) *	1989-08-21	1991-02-22	Gary H. Rasmusson	17 beta-acyl-4-aza-5-alpha-androst-1-ene-3-ones utilsiables comme inhibiteurs de l'alpha-reductase
US5032586A (en) *	1989-08-24	1991-07-16	Smithkline Beecham Corporation	7-keto or hydroxy 3,5-diene steroids as inhibitors of steroid 5-alpha reductase
US5021575A (en) *	1989-11-13	1991-06-04	Merck & Co., Inc.	Method for introducing a 1,2 double bond into azasteroids
US5100917A (en) *	1989-12-29	1992-03-31	Merrell Dow Pharmaceuticals Inc.	Novel a-nor-steroid-3-carboxylic acid derivatives
GB9002922D0 (en) *	1990-02-09	1990-04-04	Erba Carlo Spa	17 beta-substituted-4-aza-5 alpha-androstan-3-one derivatives and process for their preparation
US5098908A (en) *	1990-06-20	1992-03-24	Merck & Co., Inc.	17β-hydroxybenzoyl-4-aza-5α-androst-1-en-3-ones as testosterone reductase inhibitors
EP0462664A3 (en) *	1990-06-20	1992-11-25	Merck & Co. Inc.	Specific 17beta-thiobenzoyl-4-aza-5alpha-androst-1-en-3-ones as antiandrogenic agents
EP0462665A3 (en) *	1990-06-20	1993-06-30	Merck & Co. Inc.	Selected 17beta-polyaroyl-4-aza-5alpha-androst-1-en-3-ones as steroidal reductase inhibitors
US5061802A (en) *	1990-06-20	1991-10-29	Merck & Co. Inc.	17β-aminobenzoyl-4-aza-5α-androst-1-en-3-ones as benign prostatic hypertrophy agents
EP0462662A3 (en) *	1990-06-20	1992-08-19	Merck & Co. Inc.	17beta-n-monosubstituted adamantyl/norbornanyl carbamoyl-4-aza-5alpha-androst-1-en-3-ones and androstan-3-ones
NZ239142A (en) *	1990-08-01	1994-05-26	Merrell Dow Pharma	4-amino-delta-4-steroids; preparatory processes and pharmaceutical compositions
US5318961A (en) *	1990-08-01	1994-06-07	Merrell Dow Pharmaceuticals Inc.	4-amino-Δ4-steroids and their use as 5α-reductase inhibitors
NZ239141A (en) *	1990-08-01	1994-04-27	Merrell Dow Pharma	4-amino-delta-4,6-steroids; preparatory processes and pharmaceutical compositions
US5120847A (en) *	1990-08-27	1992-06-09	Merck & Co., Inc.	Process for iodinating or brominating the α-methylenic carbon of a secondary amide
US5091534A (en) *	1990-08-27	1992-02-25	Merck & Co., Inc.	Trialkylsilyl trifluoromethanesulfonate mediated α-methylenic carbon functionalization of 4-AZA-5α-androstan-3-one steroids
US5061803A (en) *	1990-09-24	1991-10-29	Merck & Co., Inc.	Process for making 17-beta alkanoyl 3-oxo-4-aza-5-α-androst-1-enes
US5061801A (en) *	1990-09-24	1991-10-29	Merck & Co., Inc.	Intermediate for making 3-oxo-4-aza-androst-1-ene 17β-ketones
CA2050824A1 (fr) *	1990-09-24	1992-03-25	John M. Williams	Methode de preparation de 3-oxo-4-azaandrost-1-en-17.beta.-ones
NZ241979A (en) *	1991-03-20	1996-01-26	Merck & Co Inc	Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker
IL101245A0 (en) *	1991-03-20	1992-11-15	Merck & Co Inc	Pharmaceutical compositions for the treatment of prostatic cancer
WO1992018132A1 (fr) *	1991-04-17	1992-10-29	Merck & Co., Inc.	Association pharmaceutique destinee au traitement de l'hyperplasie prostatique benigne et contenant un inhibiteur de 5 alpha-reductase
GB9115676D0 (en) *	1991-07-19	1991-09-04	Erba Carlo Spa	Process for the preparation of 17 beta substituted-4-aza-5 alpha-androstan-3-one derivatives
US5304562A (en) *	1991-10-09	1994-04-19	Ciba-Geigy Corporation	17β-substituted Aza-androstane derivatives
US5543406A (en) *	1991-12-20	1996-08-06	Glaxo Wellcome, Inc.	Inhibitors of 5-α-testosterone reductase
JP3164389B2 (ja) *	1991-12-25	2001-05-08	三共株式会社	４−アザステロイド類
EP0641209A4 (fr) *	1992-05-20	1995-08-23	Merck & Co Inc	NOUVEAUX DERIVES 17-ESTER, AMIDE ET CETONE DE 3-OXO-4-AZASTEROIDES UTILISES COMME INHIBITEURS DE 5a-REDUCTASE.
CA2135173A1 (fr) *	1992-05-20	1993-11-25	Bruce E. Witzel	Derives de 4-azasteroides
WO1993023039A1 (fr) *	1992-05-20	1993-11-25	Merck & Co., Inc.	4-aza-5a-androstan ones substituees utilisees en tant qu'inhibitors de la 5a-reductase
ATE195530T1 (de) *	1992-05-20	2000-09-15	Merck & Co Inc	17-ether und thioether von 4-aza-steroiden
US5510351A (en) *	1992-05-20	1996-04-23	Merck & Co., Inc.	Delta-17 and delta-20 olefinic and saturated 17 beta-substituted 4-aza-5 alpha-androstan-ones as 5 alpha reductase inhibitors useful in the prevention and treatment of hyperandrogenic disorders
US5620986A (en) *	1992-05-20	1997-04-15	Merck & Co., Inc.	17 urea, thiourea, thiocarbamyl and carbamyl4-azasteroid 5-reductase inhibitors useful in the prevention and treatment of hyperandrogenic disorders
US5639741A (en) *	1992-05-20	1997-06-17	Merck & Co., Inc.	17-amino substituted 4-azasteroid 5α-reductase inhibitors
WO1993023420A1 (fr) *	1992-05-20	1993-11-25	Merck & Co., Inc.	NOUVEAUX 4-AZA-5α-ANDROSTANE-3-ONES SUBSTITUES EN POSITION 7β EN TANT QU'INHIBITEURS DE LA 5α-REDUCTASE
CZ283894A3 (en) *	1992-05-20	1995-09-13	Merck & Co Inc	7beta-substituted 4-aza-5alpha-cholestanones, their use for the preparation of pharmaceutical preparations and pharmaceutical compositions containing thereof
GB9210880D0 (en) *	1992-05-21	1992-07-08	Smithkline Beecham Corp	Compounds
SK140494A3 (en) *	1992-05-21	1995-07-11	Endorecherche Inc	Inhibitors of testosterone 5-alpha-reductase activity
GB9216284D0 (en) *	1992-07-31	1992-09-16	Erba Carlo Spa	Fluorinated 17beta-substituted 4-aza-5alpha-androstane-3-one derivatives
GB9216329D0 (en) *	1992-07-31	1992-09-16	Erba Carlo Spa	17beta-substituted 4-aza-5alpha-androstan-3-one derivatives
HU212459B (en) *	1992-10-02	1996-06-28	Richter Gedeon Vegyeszet	Process for producing new 17-beta-substituted 4-aza-androstane-derivatives and pharmaceutical compositions containing them
US5278159A (en) *	1992-10-06	1994-01-11	Merck & Co., Inc.	Aryl ester derivatives of 3-oxo-4-aza-androstane 17-β-carboxylates as 5-α-reductase inhibitors
AU5323694A (en) *	1992-10-06	1994-04-26	Merck & Co., Inc.	17beta -carboxanilides of 4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors
IL107611A0 (en) *	1992-11-18	1994-02-27	Smithkline Beecham Corp	Steroid compounds and pharmaceutical compositions containing them
AP459A (en) *	1992-12-18	1996-02-14	Glaxo Wellcome Inc	Substituted 6-azaandrostenones.
US5380728A (en) *	1993-02-10	1995-01-10	Merck & Co., Inc.	Aldehyde metabolite of 17β-N-monosubstituted-carbamoyl-4-aza-5α-a
US5438061A (en) *	1993-07-16	1995-08-01	Merck & Co., Inc.	7-substituted-δ4-6-azasteroid derivatives as 5α-reductase inhibitors
TW408127B (en) *	1993-09-17	2000-10-11	Glaxo Inc	Androstenones

1994
- 1994-09-03 TW TW083108127A patent/TW369521B/zh active
- 1994-09-13 IS IS4205A patent/IS1713B/is unknown
- 1994-09-14 MY MYPI94002449A patent/MY119778A/en unknown
- 1994-09-15 AP APAP/P/1994/000669A patent/AP494A/en active
- 1994-09-15 ZA ZA947119A patent/ZA947119B/xx unknown
- 1994-09-15 ZA ZA947118A patent/ZA947118B/xx unknown
- 1994-09-15 PE PE1994250737A patent/PE15095A1/es not_active Application Discontinuation
- 1994-09-16 SG SG1996007353A patent/SG52650A1/en unknown
- 1994-09-16 ES ES94929828T patent/ES2113127T3/es not_active Expired - Lifetime
- 1994-09-16 EP EP94929828A patent/EP0719278B1/fr not_active Expired - Lifetime
- 1994-09-16 CA CA002170047A patent/CA2170047C/fr not_active Expired - Lifetime
- 1994-09-16 CN CN94193410A patent/CN1057771C/zh not_active Expired - Lifetime
- 1994-09-16 AT AT94929828T patent/ATE162199T1/de active
- 1994-09-16 AU AU78751/94A patent/AU690925B2/en not_active Expired
- 1994-09-16 IL IL11097894A patent/IL110978A/en active Protection Beyond IP Right Term
- 1994-09-16 DE DE10399022C patent/DE10399022I2/de active Active
- 1994-09-16 SI SI9430130T patent/SI0719278T1/xx unknown
- 1994-09-16 SK SK347-96A patent/SK281869B6/sk unknown
- 1994-09-16 CZ CZ1996745A patent/CZ286069B6/cs not_active IP Right Cessation
- 1994-09-16 NZ NZ274642A patent/NZ274642A/en not_active IP Right Cessation
- 1994-09-16 CA CA002462061A patent/CA2462061A1/fr not_active Abandoned
- 1994-09-16 RO RO96-00537A patent/RO117455B1/ro unknown
- 1994-09-16 PL PL94313492A patent/PL180002B1/pl unknown
- 1994-09-16 HR HR940563A patent/HRP940563B1/xx not_active IP Right Cessation
- 1994-09-16 HU HU9600656A patent/HU220060B/hu unknown
- 1994-09-16 DK DK94929828T patent/DK0719278T3/da active
- 1994-09-16 DE DE69407978T patent/DE69407978T2/de not_active Expired - Lifetime
- 1994-09-16 WO PCT/US1994/010530 patent/WO1995007927A1/fr not_active Ceased
- 1994-09-16 KR KR1019960701363A patent/KR100364953B1/ko not_active Expired - Lifetime
- 1994-09-16 EE EE9600130A patent/EE03241B1/xx unknown
- 1994-09-16 RU RU96108410A patent/RU2140926C1/ru active
- 1994-09-16 JP JP7509391A patent/JP2904310B2/ja not_active Expired - Lifetime
- 1994-10-10 SA SA94150231A patent/SA94150231B1/ar unknown
1995
- 1995-03-16 US US08/405,120 patent/US5565467A/en not_active Expired - Lifetime
1996
- 1996-03-08 BG BG100410A patent/BG62363B1/bg unknown
- 1996-03-13 OA OA60795A patent/OA10575A/en unknown
- 1996-03-15 NO NO961080A patent/NO306117B1/no not_active IP Right Cessation
- 1996-03-15 FI FI961231A patent/FI115216B/fi not_active IP Right Cessation
- 1996-08-22 US US08/708,167 patent/US5846976A/en not_active Expired - Lifetime
1997
- 1997-04-23 BR BR1100329-4A patent/BR1100329A/pt active IP Right Grant
1998
- 1998-02-12 GR GR980400317T patent/GR3026144T3/el unknown
2001
- 2001-01-03 CY CY0100002A patent/CY2219B1/xx unknown
2003
- 2003-03-07 NO NO2003003C patent/NO2003003I2/no unknown
- 2003-03-31 NL NL300122C patent/NL300122I2/nl unknown
- 2003-06-18 LU LU91027C patent/LU91027I2/fr unknown
2004
- 2004-07-26 CY CY200400002C patent/CY2004002I2/el unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0484094A2 (fr) *	1990-10-29	1992-05-06	Sankyo Company Limited	Azastéroides pour le traitement d'hypotrophie prostatique, leur préparation et usage

Also Published As

Publication number	Publication date
CZ74596A3 (en)	1996-09-11
HK1004334A1 (en)	1998-11-20
FI115216B (fi)	2005-03-31
DE69407978T2 (de)	1998-05-07
KR100364953B1 (ko)	2003-04-08
NO961080L (no)	1996-03-15
CN1131424A (zh)	1996-09-18
CY2004002I1 (el)	2009-11-04
US5565467A (en)	1996-10-15
NO306117B1 (no)	1999-09-20
SA94150231B1 (ar)	2005-05-04
ES2113127T3 (es)	1998-04-16
CZ286069B6 (cs)	2000-01-12
NL300122I2 (nl)	2003-09-01
AU7875194A (en)	1995-04-03
CN1057771C (zh)	2000-10-25
NL300122I1 (nl)	2003-06-02
EP0719278A1 (fr)	1996-07-03
HRP940563A2 (en)	1997-02-28
HU220060B (hu)	2001-10-28
DK0719278T3 (da)	1998-09-14
BG62363B1 (bg)	1999-09-30
BR1100329A (pt)	2000-06-13
AU690925B2 (en)	1998-05-07
LU91027I2 (fr)	2004-04-28
IS4205A (is)	1995-03-18
SI0719278T1 (sl)	1998-06-30
SG52650A1 (en)	1998-09-28
GR3026144T3 (en)	1998-05-29
ZA947118B (en)	1995-05-26
WO1995007927A1 (fr)	1995-03-23
JP2904310B2 (ja)	1999-06-14
RO117455B1 (ro)	2002-03-29
NO961080D0 (no)	1996-03-15
CA2170047C (fr)	2004-11-09
DE69407978D1 (de)	1998-02-19
FI961231A0 (fi)	1996-03-15
AP9400669A0 (en)	1994-10-31
NO2003003I2 (no)	2007-06-11
SK34796A3 (en)	1996-07-03
CA2170047A1 (fr)	1995-03-23
DE10399022I1 (de)	2004-01-15
HU9600656D0 (en)	1996-05-28
ATE162199T1 (de)	1998-01-15
CA2462061A1 (fr)	1995-03-23
PE15095A1 (es)	1995-06-04
US5846976A (en)	1998-12-08
JPH09502731A (ja)	1997-03-18
PL313492A1 (en)	1996-07-08
CY2004002I2 (el)	2009-11-04
IS1713B (is)	1998-12-30
ZA947119B (en)	1995-05-26
FI961231L (fi)	1996-03-15
EE03241B1 (et)	1999-12-15
PL180002B1 (pl)	2000-11-30
HRP940563B1 (en)	2000-10-31
EP0719278B1 (fr)	1998-01-14
OA10575A (en)	2002-06-25
MY119778A (en)	2005-07-29
CY2219B1 (en)	2003-04-18
IL110978A0 (en)	1994-11-28
NZ274642A (en)	1997-11-24
RU2140926C1 (ru)	1999-11-10
TW369521B (en)	1999-09-11
BG100410A (bg)	1996-09-30
SK281869B6 (sk)	2001-08-06
IL110978A (en)	1999-01-26
HUT73850A (en)	1996-09-30
DE10399022I2 (de)	2012-09-13

Publication	Publication Date	Title
AP494A (en)	1996-05-15	Androstenone derivative.
EP0719277B1 (fr)	1997-12-17	Androstenones
EP0674651B1 (fr)	1998-10-28	6-azaandrostenones substituees
US5998427A (en)	1999-12-07	Androstenones
US5708001A (en)	1998-01-13	Substituted 6-azaandrostenones
HK1004334B (en)	1998-11-20	Androstenone derivative
US5817818A (en)	1998-10-06	Androstenones
JP3824636B2 (ja)	2006-09-20	アンドロステノン
WO1996030391A1 (fr)	1996-10-03	6-azacholesten-3-ones substituees